老年ANCA相关性血管炎的长期结局
单中心队列研究纳入83例2005至2017年发病的65岁以上ANCA相关性血管炎患者,中位随访1203天,2年和5年生存率分别为83%和75%。年龄、衰弱评分和基线CRP与死亡独立相关,所有死亡患者发病时年龄均超过75岁,环磷酰胺诱导组生存更好。
要点
- 老年AAV患者2年和5年生存率分别为83%和75%。
- 年龄、衰弱评分和基线CRP与死亡独立相关。
- 环磷酰胺诱导治疗组生存优于利妥昔单抗或霉酚酸酯组。
核心结论
- 当代老年AAV患者总体预后良好,基线衰弱与包括死亡在内的疾病结局相关。
研究设计与样本
- 单中心前瞻性收集数据集,纳入2005至2017年发病的65岁以上AAV患者83例,中位随访1203天。
主要发现
- 整体队列2年生存率为83%(95%CI 75,92%),5年生存率为75%(95%CI 65,86%)。
- 年龄、衰弱评分和基线CRP与死亡独立相关,所有死亡患者发病时年龄均超过75岁。
- 环磷酰胺诱导组患者 tended to be younger,且生存优于利妥昔单抗或霉酚酸酯组。
关键数值与推荐
- 前3个月口服泼尼松龙中位累积剂量为2030 mg,仅1例接受静脉糖皮质激素。
临床怎么用
- 老年AAV患者可采用低剂量糖皮质激素方案(避免静脉甲泼尼龙)有效治疗。
- 基线衰弱评分可能有助于预后评估。
局限性
- 单中心回顾性队列,样本量83例,环磷酰胺组与利妥昔单抗/霉酚酸酯组比较未报告统计学检验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: ANCA-associated vasculitis (AAV) is a small vessel vasculitis that commonly presents in the elderly. However, there are few long-term outcome data for these patients. Here, we assessed long-term outcomes in a single-centre cohort of elderly patients with AAV. Additionally, we tested whether a pre-morbid frailty score could aid prognosis. METHODS: Using a prospectively-compiled dataset, we investigated patients over the age of 65 who presented with AAV between 2005 and 2017 to a regional vasculitis centre. We used a Cox model to determine the factors associated with mortality. We also compared outcomes in pre-specified subgroups stratified by baseline frailty score, ANCA serotype and induction immunosuppression (with cyclophosphamide, rituximab or mycophenolate mofetil used as the main glucocorticoid-sparing agent). RESULTS: 83 patients were included in the study and were followed for a median of 1203 days. Median age was 74 years (range 65-92). Two- and five-year survival in the overall cohort were 83% (95% CI 75, 92%) and 75% (95% CI 65, 86%), respectively. The median cumulative dose of oral prednisolone was 2030 mg during the first three months. Only one patient received intravenous glucocorticoids. Age, frailty score and CRP at presentation were independently associated with mortality; all deaths occurred in patients aged over 75 at presentation. Patients treated with a cyclophosphamide-based induction regimen tended to be younger than those treated with rituximab or mycophenolate mofetil. Survival was better in the cyclophosphamide-treated group. CONCLUSION: In the contemporary era, the overall prognosis of AAV in elderly patients is good. Baseline frailty associates with disease outcomes including mortality. A low-dose glucocorticoid regimen (avoiding intravenous methylprednisolone) can be used to treat AAV effectively in elderly patients.
引用
- McGovern D, Williams SP, Parsons K, et al. Long-term outcomes in elderly patients with ANCA-associated vasculitis. Rheumatology (Oxford). 2020. PMID: 31794032. doi:10.1093/rheumatology/kez388
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。